Beata Mladosievičová
Although a significant progress in early diagnosis and treatment of cancer has been achieved in the recent years, patients
with heart damage induced by oncological therapy remain a considerable medical problem. Anticancer drug-related cardiotoxicity
belongs to the leading causes of treatment-associated mortality in cancer survivors. Evaluation and control
of the cancer patient’s cardiovascular status and risk factors before, during, and after treatment is crucial for improving
their outcome and quality of life. There are more than 20 cardiotoxic cytostatics and several targeted cancer drugs. Their
list grows each year. This review will focus on recent literature regarding the most serious cardiovascular complications
during active cancer therapy with cytostatics and targeted agents as well as after its completion.